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Purpose: To report the outcomes of two cases of infectious scleritis with severe scleral thinning managed using
combined mechanical debridement, cryopreserved umbilical amnion (UA) and amniotic membrane (AM) grafts,
and antimicrobial therapy.
Observations: Two patients presented with severe infectious scleritis with progressive scleral melts secondary to
Pseudomonas aeruginosa subsequent to pterygium surgery and intravitreal injection, respectively. Surgical
debridement was followed by UA grafting, AM transplantation, and antimicrobial therapy. Epithelialization and
vascularization were seen within 1–4 weeks post-operatively. At last follow up of 5–6 months, the structural
integrity of the sclera remained preserved with no infection recurrence, graft necrosis, or wound dehiscence.
Conclusions and importance: This case series highlights the utilization of UA grafting along with AM trans
plantation and topical and systemic antibiotics to preserve the globe in cases of severe infectious scleritis.

1. Introduction

2. Findings

Infection is a serious but rare cause of scleritis, representing about
5–10% of all scleritis cases.1 Infectious scleritis (IS) is associated with
longer resolution times and worse outcomes compared to non-infectious
causes,2 and can result in a number of vision-threatening complications
including cataracts, glaucoma, endophthalmitis, and loss of the globe.3,4
Topical and systemic antibiotic regimens alone are often inadequate, as
the biofilm, avascularity of the sclera, and dense collagen network limit
antibiotic penetration and reduce bacterial susceptibility.5,6 Thus, sur
gical debridement is often used to facilitate antibiotic access.3,7,8
A number of studies have reported favorable outcomes using
debridement in conjunction with antibiotics for the treatment of IS.4,5,7
In cases with severe thinning, a patch graft is often used to help maintain
structural integrity of the globe. Umbilical amnion (UA) and amniotic
membrane (AM) grafts have been used extensively in ophthal
mology,9,10 however, their use in the treatment of IS and for severe
scleral thinning has not been reported. Herein, we describe two cases of
IS that were successfully treated with mechanical debridement, UA
grafting and AM transplantation, and antimicrobial therapy.

2.1. Case 1
A 73-year-old man presented with persistent pain OS despite treat
ment with topical antibiotics for approximately 2 weeks. He had a his
tory of pterygium surgery with mitomycin-C in this eye 5 years prior.
The visual acuity was 20/200 and intraocular pressure (IOP) was 11
mmHg. Examination revealed 9 mm × 5 mm scleral necrosis nasally
with purulent material and scleral plaques. There was significant scleral
thinning with uveal show but no uveal prolapse (Fig. 1). There was also a
temporal scleral plaque without active scleral necrosis. The patient had
inferior keratic precipitates (KPs) and 2+ nuclear sclerosis (NS). The
diagnosis was confirmed to be infectious scleritis with cultures growing
Pseudomonas aeruginosa.
The patient was taken to the operating room. Toothed forceps and a
57-blade were used to carefully dissect the nasal scleral plaque, for
which pathologic evaluation demonstrated dense calcification. The
necrotic scleral material was then debrided with a 57-blade and sent for
additional cultures. Dilute ceftriaxone was used to wash out the area of
necrotic sclera. A 0.75 cm × 1.0 cm UA patch graft (AmnioGuard; BioTissue, Miami, FL) was placed over the area of scleral thinning and
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secured into place using 16 interrupted 7-0 Vicryl sutures. The graft was
trimmed at the edges so that it was flush with the edge of the corneal
limbus. Next, a 2.5 cm × 2.0 cm AM (AmnioGraft; Bio-Tissue, Miami, FL)
was cut in half. The first half was placed over the UA patch graft, and
was secured in place with Tisseel fibrin glue (Baxter, Deerfield, IL). The
other half was placed over the first AM and secured with 4 interrupted 70 Vicryl sutures at the corners of the graft. Subconjunctival aliquots of
ceftriaxone were administered surrounding the area of infection, and the
eye was patched and shielded. Post-operative drop regimen included
fortified tobramycin 14 mg/ml and topical moxifloxacin 0.5% every 2 h
with a taper over six weeks, oral ciprofloxacin 500 mg twice daily for
four weeks, and cyclopentolate 1% twice daily for six weeks. Topical
prednisolone acetate 1% four times daily was started three weeks after
surgery and was tapered off over the ensuing 10 weeks.
On post-operative day 1, the patient’s vision was 20/300. The UA
with overlying AM remained in good position. Slit lamp examination
revealed 3+ conjunctival injection, inferior KPs, a small hyphema, and
2+ NS. At 1 week, the visual acuity was counting fingers due to wors
ening of the cataract, and IOP was 8 mmHg. Examination revealed that
the UA remained in good position with staining inferiorly and dissolu
tion of the overlying AMs. There was 3+ conjunctival injection diffusely,
a chemotic plica, an area of depression between the plica and border of
the AM graft, inferior KPs, a sliver hyphema, and 2–3+ brunescent NS.
By 1 month, the visual acuity remained at counting fingers, and IOP was
10 mmHg. Examination revealed similar findings as 1 week, however
the UA showed early vascularization with no staining present. The
conjunctival inflammation had decreased to 2+ injection and hyphema
had resolved. At 3 months, visual acuity had slightly improved to 20/
400, and IOP was 12 mmHg. Examination revealed that the UA had
dissolved with residual vascularization and no staining, a quiet con
junctiva, cornea with no infiltrate or epithelial defect, and 3+ brunes
cent NS with pigment on the anterior capsule (Fig. 1). Six months postoperatively, the patient underwent cataract extraction with intraocular
lens placement. His 1-week post-operative visual acuity was 20/40.

subconjunctival cefazolin 50 mg/ml and gentamicin 40 mg/ml. Despite
this intervention and inpatient treatment with intravenous levofloxacin
750 mg daily and hourly topical fortified tobramycin 14 mg/ml and
topical moxifloxacin 0.5% for seven days, the patient had progressive
scleral melt and was taken to the operating room for more definitive
surgery.
The surgery was performed similar to that described for Case 1. The
necrotic inferotemporal scleral material was resected and sent for pa
thology evaluation. The area of scleral necrosis was measured to be 5
mm × 9 mm, and a UA patch graft was cut to size and secured with
interrupted 9-0 Vicryl sutures. A 8 mm × 12 mm AM graft was then
placed over this area, secured with Tisseel fibrin glue, and sutured on all
sides with interrupted 7-0 Vicryl sutures. The corneal defect was then
addressed by applying a 10 mm x 10 mm AM fixated with Tisseel fibrin
glue. A second layer of 18 mm × 15 mm AM was then placed over the
first layer and sutured into place with interrupted 9-0 Vicryl sutures in a
mattress fashion. A subconjunctival injection of ceftriaxone was
administered inferotemporally and the eye was patched and shielded.
Post-operative regimen included topical fortified tobramycin 14 mg/ml
and topical moxifloxacin 0.5% every 2 h with a taper over six weeks,
ciprofloxacin ophthalmic ointment four times a day for four months,
oral moxifloxacin 400 mg daily for four weeks, atropine 1% twice daily
for six weeks, and topical prednisolone acetate 1% twice daily with a
taper over four months.
At post-operative day 1, the visual acuity was light perception, and
IOP was 3 mmHg. Exam revealed 2+ conjunctival injection, scleral
thinning inferotemporally covered by UA and AM, cornea with a 9 mm
× 8 mm epithelial defect covered with double-layered AM in good po
sition, and a hazy view beyond the cornea. At 1 week, visual acuity
remained light perception and IOP was 2 mmHg. Examination revealed
2+ conjunctival injection, UA in good position inferotemporally
covering the scleral thinning, and a 4 mm × 4.5 mm corneal epithelial
defect with ~50% thinning centrally. At 2 weeks post-operatively, the
entire ocular surface was fully epithelialized. By 1 month, vision was HM
and IOP was 2 mmHg. Examination revealed 2+ conjunctival injection,
and the area with UA was well vascularized. The cornea had diffuse
edema, a scar paracentrally, and irregular thinning (greatest ~50% loss
nasally). At 5 months, examination revealed a white and quiet con
junctiva, well vascularized area previously covered by UA, and similar
corneal findings (Fig. 2). The visual acuity reverted back to light
perception, and the patient was confirmed to have an afferent pupillary
defect. At this point, treatment options including penetrating kerato
plasty and Boston Keratoprosthesis were discussed with the patient,
however given the poor visual prognosis, the patient preferred
observation.

2.2. Case 2
A 64-year-old female was referred to the Wills Eye Hospital Emer
gency Room for a culture-positive infectious corneal ulcer secondary to
Pseudomonas aeruginosa that had failed topical antibiotics and had pro
gressed to suspected endophthalmitis. The patient underwent an intra
vitreal tap and injection for presumed keratitis-related endophthalmitis,
and subsequently developed scleritis two weeks later in the location of
the intravitreal injection, at which point she was referred to our practice.
The visual acuity was hand motion and IOP was 4 mmHg. Slit lamp
examination was notable for a 4 mm × 6.5 mm inferotemporal scleral
abscess that was non-contiguous with the cornea, a diffusely edematous
corneal stroma with patchy tissue loss (ranging from 40 to 80%), a 9
mm × 10 mm corneal epithelial defect, and a 3.5 mm hypopyon (Fig. 2).
The patient was taken to the operating room for corneal biopsy and a
single-layer AM graft covering the involved sclera, with injection of

3. Discussion
Bacterial etiologies comprise the majority of IS cases, with Pseudo
monas aeruginosa being the most common infectious agent.3 Bacterial
invasion is facilitated by proteinases that degrade the basement

Fig. 1. Case 1. Patient presented with 9 mm × 5 mm scleral melt (A) that was surgically managed using umbilical amnion patch grafting and amniotic membrane
transplantation. Post-operative photos after 1 day (B), 1 month (C), and 3 months (D) are presented.
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Fig. 2. Case 2. Patient presented with a 4 mm × 6.5 mm inferotemporal scleral abscess, a 9 mm × 10 mm corneal epithelial defect, and a 3.5 mm hypopyon (A, E).
Surgical intervention resulted in progressive healing and epithelialization at 1 day (B, F) and 1 week (C, G), with complete epithelialization at 8 weeks (D, H).

membrane and cause cell lysis as well as exotoxins that cause stromal
necrosis.11,12 Furthermore, host lysosomal enzymes and oxidative sub
stances produced by neutrophils, keratocytes, and epithelial cells may
significantly contribute to the destruction caused by Pseudomonas aer
uginosa.13 This infectious assault and resulting inflammation can even
tually lead to scleral ischemia, necrosis, and thinning.
In less than 20% of cases of IS, medical therapy alone (including
systemic, topical, and subconjunctival antibiotics) results in complete
resolution of infection. There are several possible explanations for this
relatively low success rate, including the sclera’s dense collagen fibers
and avascularity. As a result, surgical debridement is often used
adjunctively to decrease the microbial load and improved antibiotic
delivery.4,14 Early mechanical debridement combined with antimicro
bial therapy has been demonstrated to decrease the length of treatment,
increase the rates of globe preservation, and improve prognosis for
IS.4,14–16 Although well-described in the literature as an effective sur
gical technique for infectious scleritis,17 cryotherapy was not utilized in
either of these cases due to the severe degree of scleral thinning and
concerns that cryotherapy may increase the risk of perforation.
In this case series, mechanical debridement, UA and AM grafting,
and antimicrobial therapy successfully preserved the globe in two cases
of necrotizing IS and scleral melt. Case 1 developed IS after pterygium
surgery using mitomycin-C and Case 2 developed IS secondary to an
intravitreal injection for presumed keratitis-associated endophthalmitis.
Scleral melting and IS are well reported complications following pte
rygium surgery.5–7 In one series including three cases of Pseudomona
s-associated keratoscleritis occurring after pterygium excision, early
debridement, topical and systemic antibiotics, and low-dose oral pred
nisone resulted in successful outcomes.18 On the other hand, there has
only been one prior report of necrotizing IS following intravitreal in
jection,19 but several reports of IS following sub-Tenon injection.20–22
This highlights the fact that although rare, ocular injection can result in
IS and severe complications such as scleral melt. Case 1 had visual re
covery following cataract surgery, whereas Case 2 did not regain func
tional vision following our surgical treatment; this latter case had an
afferent pupillary defect along with presenting visual acuity worse than
20/200 vision and endophthalmitis, which are known poor prognostic
indicators in IS.5
Various tissues and materials have been used to cover the sclera
following debridement of large areas.23 While AM transplantation has
been employed in the treatment of IS, most reports involve the use of
various tissue grafts in conjunction with AM. Zheng et al.24 successfully
used fascia lata grafts in conjunction with AM following surgical
debridement for IS, and Siatiri et al.25 restored globe integrity and
treated inflammation in a case of necrotizing IS caused by Pseudomonas
aeruginosa using debridement, scleral graft, tenonplasty, and AM trans
plantation. Finger et al. described the use of super-thick amniotic

membrane grafts for ocular surface reconstruction after resection of
conjunctival melanoma, squamous cell carcinoma, sebaceous carci
noma, and atypical pterygium, and for scleral necrosis; retention and
complete epithelialization were achieved in all cases.10 In the present
case series, a thick layer of UA was used to cover the sclera which was
then covered with thinner AM.
Anatomically, the UA contains the AM as its outer layer and a loose,
proteoglycan-rich Wharton’s jelly as its inner layer. Both the UA and AM
contain collagen, fibronectin, glycosaminoglycans, and HC-HA/PTX3,
however UA is about 10 times thicker than AM alone.26–28 The UA is
advantageous compared to other tissue and synthetic materials (such as
sclera, cornea, dermis, and autologous fascia lata) because it is readily
available off-the-shelf, is relatively transparent for good cosmetic out
comes, is relatively thick and flexible for secure handling, suturability,
and filling voids, has low immunogenicity, and has anti-inflammatory,
anti-scarring, and pro-regenerative properties. Hence, UA may prevent
the ongoing necrotic process by reducing infiltration and inducing
apoptosis of activated neutrophils29,30 and macrophages.31–33 Addi
tionally, one key biological modulator present in both UA and AM,
HC-HA/PTX3, upregulates IL-10, downregulates IL-12, and polarizes
macrophages toward anti-inflammatory phenotype, all of which play an
integral role in the healing process.26–28 Moreover, the UA used in our
cases was well vascularized within 1 month of surgery, a feature which
prevents infection and further thinning. Such an effect has also been
shown in cutaneous wounds.34–38 Together these conditions may pro
vide an optimal healing environment and facilitate recovery of an
inflamed ocular surface as shown in these cases.
4. Conclusions
This case series highlights the utilization of UA to maintain the
scleral integrity and, along with AM transplantation and antibiotics,
preserve the globe in cases of severe IS.
Patient consent
Written consent to publish deidentified medical information and
clinical photographs was obtained from the patients. This report does
not contain any personal information that could lead to the identifica
tion of the patients.
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